Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary
October 28, 2026
Earnings Call Speaker Segments
Eric Linn
executiveThanks, and good morning everyone. I'd like to welcome you to Mirion's earnings conference call for the third quarter of 2026. With me this morning are Tom Logan, Mirion's Founder, Chairman, and CEO, and Brian Schopfer, Mirion's CFO and President of the Medical Group. Before we get into today's prepared remarks, please let me remind you that during this call we will be making forward-looking statements, and actual results could differ materially from what those forward-looking statements project. The factors that might cause actual results to differ are covered in our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and in Mirion's other SEC filings under the caption Risk Factors. Any quarterly references in today's discussion relate to the third quarter ended September 30th, 2026, unless otherwise noted. Today's comments will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. You can find a reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix of the presentation that accompanies today's call. All of our earnings materials are available in the investor relations section of our website at www.mirion.com. With that, I'll hand the call over to Tom, who will begin on panel three.
Tom Logan
executiveEric, thank you for that, and good morning, everyone. We put out our Q3 results yesterday after the market closed, and I'm glad to report that the quarter shows continued favorable momentum throughout our markets. We posted solid orders — among them $140 million in large opportunity wins — along with revenue growth driven by backlog conversion, plus full-year guidance calling for mid to high teens organic revenue growth in Q4. I'll start with orders, which remain the key bellwether for our business. Once again we had a strong quarter there, with orders up 62% year-over-year, excluding M&A, reaching $340 million. The nuclear power end market was the top performer, with an impressive 105% increase, also excluding M&A. Now on revenue: back in July, I mentioned we were gearing up for a solid pickup in the second half. Organic revenue for the third quarter was up 6.5%, and we remain on course for mid to high teens organic growth in Q4. Our backlog keeps expanding and is doing its job—turning into revenue at a quicker pace. That momentum, along with the visibility we have across nine months, informs the updated full year 2026 guidance Brian will walk you through. I'd add that we anticipate net leverage improving to about 2.6 x by the end of the year, driven by both earnings growth and the cash generation we expect in the fourth quarter. I want to emphasize that the cost attached to our debt structure is quite low—the average coupon sits under 3%, which is less than half of what straight debt would carry. As a result, our effective leverage exposure is arguably much smaller than a lot of people would infer from looking at screens. Regarding guidance, and before we turn to panel four, I'd like to speak to the 2028 margin target we announced earlier, which we now see as overly aggressive. External factors have held back our medical organic growth over the past few years, and we expect margin expansion at Paragon to fall short of the original expectations. On top of that, I'm putting major investment dollars behind AI and cybersecurity so we can fully capitalize on the accelerating demand we're seeing in our end markets. We've got a long track record of expanding margins. That said, we're staring at a once-in-a-generation opportunity, and it would be shortsighted to chase a near-term margin target while sacrificing something we think will create long-term shareholder value. Rather, we're focused on growing margins every year through operating leverage, software, procurement, and self-help efforts. Let's move to panel four, which lays out the details of our Q3 order book against Q3 of last year. Excluding M&A, core orders were up 62%. Overall orders reached $386 million, an 85% increase, which includes $46 million from Paragon and Certrec — this happened even with the Chinese de-booking we talked about earlier during our Q2 call. Outside of that de-booking and M&A, Nuclear & Safety orders climbed by about $130 million, helped by nuclear power end-market orders doubling. Labs & Research orders nearly doubled as well, partly because of two large Department of Energy orders. Defense & Diversified posted double-digit order growth, and Medical orders were up roughly $19 million versus a year ago, reflecting strong intake in the RTQA end market. All told, the Medical segment saw orders increase in each of its three end markets. Panel five gives a helpful view of the broader order trend. Here's a chart showing orders on a trailing 12-month basis, with M&A taken out, and I think the picture is pretty clear on its own. You can see the step-up that began in Q4 of last year, and it picks up even more momentum as we move through Q3. On that trailing 12-month measure, orders are up 37% when you exclude M&A. That increase is driven largely by expansion in the nuclear power end market, and what's important is that the installed base was the single biggest year-over-year contributor. As a reminder, we're present in over 98% of the world's nuclear reactors, and about 80% of our nuclear power revenue comes from the fleet that's operating today. This isn't growth that depends on unpredictable new build timelines; it's growth that comes from reactors running right now. This ties back to something I mentioned during the previous quarter's call — you can see it on panel six — namely the waves of demand coming from our installed base customers. First, there's the catch-up capital spending following decades of severe capital rationing; second, life extensions and power uprates, which deliver capacity gains in the near term; and third, the digital transformation that is starting to gain traction. The key point I want to make today is that all three of these waves are now starting to materialize. Catch-up capital spending is the first wave. According to the August NEI report, capital spending across the U.S. fleet came to $9.7 per megawatt-hour in 2025, compared with $7.8 in 2024 and $6.4 in 2021. Life extensions and power uprates make up the second wave. Over the past few weeks, uprate announcements came in at roughly 1.5 GW in total: 890 MW from Constellation's units across Illinois, Pennsylvania, and New Jersey; 433 MW from Vistra's fleet in Pennsylvania and Ohio; and 190 MW at Calvert Cliffs in Maryland. Beyond those uprates, 96% of U.S. reactors have now received approval for 20-year life extensions, and the downstream investment work this requires is already in progress—and there may be additional runway. In July, the NRC put forward a rule that would permit license renewals of as much as 40 years, twice the current 20-year cap. If that rule is finalized, operators would be able to plan for decades of further operation, and each extra year of operation translates into sustained demand for the instrumentation, software, and services we offer. Digital transformation is the last of these waves. Earlier, we won a contract to modernize, in digital form, a portion of the reactor protection systems at unit one of a big nuclear station already in operation. That gear has now been delivered, installation starts in November, and we anticipate further chances with subsequent units. This shows plainly how digital transformation is shifting from idea to firm action throughout our installed base, and this wave is still at a very early stage. Crucially, none of these three waves depends on things that may happen later, above all the expansion of data centers. Operators of fleets have already locked in long-term commitments built on a sweeping shift in market dynamics—and those dynamics will almost certainly persist, since global electrical generating capacity is running a substantial deficit. What probably comes next is a capital growth cycle lasting many years, perhaps many decades, touching every category of instrumentation, software, and services we supply to nuclear power plant operators. Now let me move to panel seven, our backlog, which shows the positive direction in revenue recognition. The total backlog is $1.25 billion at present, compared with $816 million one year earlier. Paragon and Certrec contribute to that growth, but even excluding M&A activity, we anticipate a significant increase in how much of our expected backlog converts across each subsequent year. We project $292 million in current-year recognition from backlog, compared with $212 million a year earlier. Backlog for 2027 stands at $443 million, up from $285 million. Combining those figures gives us approximately $735 million to be recognized across Q4 2026 and the entirety of 2027—more than $200 million above where we stood at this time last year. That captures the essence: expanding total backlog is driving higher near-term revenue recognition. I'll wrap up my prepared remarks on panel eight, which illustrates the better revenue visibility that backlog delivers. At the midpoint of our revised guidance, full-year revenue coverage now reaches 95%, compared with 94% at this stage in each of the prior three years. The math works like this. Revenue year-to-date through September is $802 million. We expect $292 million of backlog to convert in the fourth quarter, and combined that comes to about $1.09 billion, measured against the $1.15 billion midpoint of our full-year revenue guidance. What remains to be won is roughly $60 million, and the bulk of that is intra-quarter Medical business—revenue of the sort we have delivered historically—plus Paragon's PeAks business, which isn't reflected in backlog. Looking at what we've done so far this year plus the backlog we carry into Q4, a good deal of uncertainty around the full year has been removed. To sum up: order activity is strong, a growing backlog is converting into sales, and we remain on course for organic revenue growth in the mid to high teens during the fourth quarter; in our view, the generational tailwinds supporting nuclear power have only begun to show up in our numbers and should leave us well positioned for strength in 2027. On that note, I'll pass it over to Brian, who will walk you through the financials and the details of our updated guidance. Brian?
Brian Schopfer
executiveThanks, Tom, and good morning to all of you. I'll take over the prepared remarks at slide nine, where our financial performance is laid out. Total revenue for the third quarter reached $278 million, a 24.5% increase over the third quarter of last year. Organic revenue growth stood at 6.5%, and both segments improved relative to what we saw in the first half of the year. Adjusted EBITDA for the third quarter was $65 million, which is 23.7% higher than last year. Margins were 23.3% versus 23.5% last year, and they came in below the modest year-over-year expansion we guided in July. Nuclear & Safety margins shrank, largely because of one-time adjustments to legacy projects at Paragon and because of headwinds in our Sensing and North America businesses. A 200 basis point expansion in Medical margins more than made up for that. If you exclude a 50 basis point headwind from M&A, 50 basis points from certain one-time items, and almost 70 basis points from AI-related initiatives in the quarter, margins would have expanded approximately 150 basis points; on that last point, we've spent almost $4 million in year-to-date operating expenses on AI initiatives that we expect to drive significant value in the coming years. Note that through three quarters, we've already actioned AI investments in excess of our initial full-year budget. During Q3, we took advantage of favorable conditions and bought back $56 million in stock, representing 3.6 million shares. That wraps up the initial $100 million buyback plan we announced in December of 2024, and in August the board gave the green light to a fresh $250 million program, with $235 million still available. Adjusted free cash flow came in at $47 million for the quarter, pushing our year-to-date figure to $107 million—twice what it was a year earlier—which works out to 58% conversion of adjusted EBITDA over the first nine months. Finally, as Tom mentioned, we saw strong Q3 order growth in both segments. Slide 10 walks through the ongoing momentum in our substantial opportunity pipeline. During Q3, we booked $140 million in large opportunities—or $122 million net once you exclude the Chinese new build de-booking that we talked about in July. Among the awards we'd already flagged in July were the European installed base order and the U.S. Department of Energy order. On the new awards side, we landed a Paragon order with the U.S. Department of Energy as well as an Egyptian large-scale new build order; that puts our year-to-date awards at $244 million, which is $234 million above where we stood in the same period last year. The key point is that none of the large opportunities in our pipeline have been lost this year. For Q4, we're aiming for roughly $125 million in additional awards. Two orders worth over $80 million are part of that $125 million figure — they were actually booked in September and aren't sitting in our backlog right now because the project is still waiting on EU funding approval. Both relate to new builds in France and fall under our strategic alliance with EDF. Before we get into the quarterly financial results, I want to give an update on the nuclear power end market, which you'll find on slide 11. On the nuclear power side, orders excluding M&A were up 105% in Q3, or 108% stripping out FX. And if we also set aside the Chinese de-booking we discussed last quarter, orders would actually have been up 134%. We booked $16 million in SMR orders this quarter, which is roughly comparable to the $17 million booked in Q3 of last year, and that takes year-to-date SMR orders to $54 million, coming from 11 separate SMR designers. Organic revenue for nuclear power was up 14%, helped by expansion in the installed base as well as SMRs. That marks a real inflection from the flat organic growth we posted in the first half, since the backlog we've been accumulating has started turning into revenue. We're still confident nuclear power will deliver double-digit organic revenue growth for the full year, and that implies even more acceleration in Q4. Now let's walk through the quarterly financials, starting on slide 12. For the third quarter on a consolidated basis, revenue climbed 24.5%, reaching $277.8 million. Acquisitions accounted for roughly 18.6% of that increase, driven mainly by Paragon, though a 60 basis point currency drag partly offset it. Organic growth was 6.5%, slightly below the high single-digit outlook we shared in July. Keep in mind that we closed the Certrec deal on July 31st, 2025. Third-quarter adjusted EBITDA reached $64.8 million, an improvement of 23.7% over the same period last year. Adjusted EBITDA margin was 23.3%, compared with 23.5% a year earlier, as the expected decline in Nuclear & Safety outweighed margin gains in Medical. Excluding Paragon, the margin would have been 23.9%, representing an increase for the quarter. For this quarter, adjusted EPS was $0.12 a share—unchanged from the $0.12 we posted a year ago and above the $0.11 comparable figure that includes stock-based compensation. Just to remind everyone, beginning in 2026 stock-based compensation will be folded into how we calculate adjusted EPS. You'll find an adjusted EPS reconciliation slide in the appendix laying out the details for your modeling. Turning to the Nuclear & Safety segment, slide 13, revenue for Q3 reached $194 million, up 34%. Organic revenue was 6.3%, in line with the guidance we gave in July. As noted earlier, revenue in the nuclear power end market rose 14% organically, powered by the installed base and SMRs. Labs & Research declined, though that was partially balanced out by gains in Defense & Diversified. Paragon is still delivering impressive results — quarterly revenue climbed 12%, and it's up 22% for the year so far. We're still on course to achieve year-over-year growth of at least 25% for Paragon. Adjusted EBITDA increased 23%, reaching $49.8 million. Margins contracted, coming in at 25.7% versus 28.1% a year ago. As we mentioned back in July, that's due to dilution from Paragon — including margin pressure stemming from those legacy contracts — plus mix and the fact that we're lapping a reduction in incentive compensation in 2025. If you set aside Paragon and the impact of prior-year incentive compensation adjustments, margins would have come in at 28.3%, which would represent an increase for the quarter. Moving now to the Medical segment, which is on slide 14. Third quarter revenue was $84 million, up 6.7%. Organic revenue was up 6.7% as well, which came in slightly under the high single-digit increase we'd anticipated back in July. We did see quite strong order growth during the quarter, but the timing of those orders leaned heavily toward the latter part of September. Each of our three end markets added to organic growth. RTQA was the biggest contributor, mirroring ongoing momentum in the OEM sector. On an encouraging note, Nuclear Medicine and Dosimetry Services — both of which had declined during Q2 — posted organic growth in Q3. For the Medical segment, Q3 adjusted EBITDA came to $31.7 million, which is 12.4% higher than a year ago. Margins widened 200 basis points, reaching 37.8%, thanks to RTQA's performance along with operating leverage from stronger revenue growth. Even though Medical margins did expand, the amount of that expansion fell short of what we had expected internally, partly because of a one-time quality cost impact tied to a specific product in our Nuclear Medicine end market. Moving to adjusted free cash flow on slide 15; we produced $47 million during the third quarter, bringing the first nine months of 2026 to $107 million, which works out to 58% conversion of adjusted EBITDA, compared with $53 million and 35%, respectively, last year. Net working capital served as a source of cash this quarter, and we anticipate that pattern carrying into Q4.
Brian Schopfer
executiveLower cash taxes remain a tailwind for us as well, and we now expect them to come in above our original guidance. Our capital structure is another positive, with the blended cost of debt for the entire year projected at roughly 2.8%. Net leverage at quarter end stood at 3.1 x, or 2.8 x if you exclude the opportunistic share repurchases completed during the quarter. Assuming no share repurchases or M&A in the fourth quarter, we anticipate net leverage improving to about 2.6 x at the midpoint by year-end. If you turn to slide 16, we're updating our full-year 2026 guidance, which now benefits from clearer visibility with just one quarter remaining. Total revenue growth guidance moves up to 24%-25% from 22%-24%, and that includes acquisition-related tailwinds plus a modest full-year FX tailwind driven by the euro. Organic revenue growth guidance also rises, to 7%-8% from 5%-7%, capturing the inflection seen in second half performance and the conversion of our growing backlog. For fourth quarter organic revenue growth, we expect consolidated organic revenue growth in the mid to high teens. Medical should grow mid-single digits plus, while Nuclear & Safety, including Paragon's December results, should grow high teens plus on the strength of nuclear power; adjusted EBITDA is now forecast at $285 million-$292 million with margins of approximately 24.7%-25.2%; we are keeping the low end of our previous adjusted EBITDA dollar range while bringing down the high end, which reflects third quarter margin headwinds in Nuclear & Safety and weaker than expected Medical margin expansion. Even with that, this range implies fourth quarter adjusted EBITDA margin expansion for the total company versus last year. Slight margin pressure is expected in Medical owing to prior year comps, primarily incentive comp and other one-time items. For Nuclear & Safety, we anticipate the strongest margin expansion quarter of the year. On adjusted free cash flow, guidance rises to $170 million-$185 million from $155 million-$175 million, equal to 60%-63% conversion of adjusted EBITDA, up from 54%-58%; our adjusted EPS range narrows to $0.50-$0.54 per share from $0.48-$0.55 per share previously. Finally, our guidance now incorporates a fourth quarter euro to dollar rate of $1.12. With that, we're happy to take your questions.
Tomo Sano
analystGood morning, everyone.
Tom Logan
executiveHello, Tomo.
Brian Schopfer
executiveHi, Tomo.
Tomo Sano
analystThanks. Perhaps I could focus just on Nuclear margins. I realize part of that pressure comes from the legacy Paragon mix, along with the investment you're putting into areas such as AI. If we set those headwinds aside, how would you frame the underlying margin trajectory for the Nuclear business? As we head into 2027, ought we to expect those headwinds to start easing and more of the underlying operating leverage to show through? Thanks.
Tom Logan
executiveYes, Tomo, let me take that first. My perspective remains quite positive. We believe there's huge opportunity to generate margin expansion across the board. As I mentioned, essentially three broad themes are leading us to move away from that 30-point near-term EBITDA margin target. One, plainly, is AI and cyber, where if we consider our current position, our outlook on the promise and the potential, and also on the cyber side, the risk — we're spending much more on AI, and probably will keep doing so, than we expected three years back when those targets were set overall. Second is Paragon. On Paragon, to add a bit more detail to the picture. Looking at margins in their core business, those are quite strong; they're net-accretive to Mirion margins overall; but where we stand — I wouldn't call it upside down — but where we're getting better insight really concerns a large-scale product development initiative that is rounding out our positioning in instrumentation and control for nuclear power plants. There, spending runs a little above what we anticipated, and I believe the overall timeline for achieving margin accretion in this category will stretch out somewhat. All of which means we're delighted with Paragon. We're performing very well on the integration campaign overall. But since we've developed more insight into how this piece of their business will probably evolve over time, we're simply adopting a more conservative view of it. The last element is Medical. As mentioned, largely because of the macro, we've experienced a two-year flat spot in Medical sector growth overall. To be clear, this issue affects the whole sector; we've outperformed our competitors here. We are seeing a recovery; but again, relative to where we stood three years ago, we've simply rerated our expectations overall. Everything we've discussed historically regarding the continuing potential to drive improved absorption dynamics, improved procurement initiatives, to leverage the internal productivity of AI to push greater product volume through AI-enabled services, and all the other self-help measures remains in place. Again, we have a long track record of margin expansion and our internal targets are very aggressive; we've just removed that 30-point near-term target because we felt it had become a distraction and was creating a bit of an overhang.
Tomo Sano
analystThanks, Tom. Perhaps a question about capital allocation. As free cash flow gets better and leverage declines, how do you view the priorities across M&A, additional deleveraging, and share repurchase heading into 2027?
Brian Schopfer
executiveYes, so what we've discussed publicly, Tomo, is essentially a sort of 20/40/40 framework. Roughly 20%-ish of our cash flow is directed to CapEx and organic growth efforts. Around 40% we've considered through an M&A lens, and those will all be bolt-on-type transactions. Then the remaining 40% goes really back to the shareholder, correct? We have no dividend at present, so that is almost entirely via share repurchases. I think we'll keep assessing that. I should mention, we're extremely pleased with how the company has performed on cash flow. We anticipate maintaining momentum there. I believe we're strongly positioned for that to persist.
Tomo Sano
analystExcellent, Brian. That really helps. I'll stop there. Thank you.
Brian Schopfer
executiveAppreciate it, Tomo.
Quinn Fredrickson
analystMorning, everyone. Appreciate you taking our questions.
Tom Logan
executiveHi there, Quinn.
Quinn Fredrickson
analystI'd like to begin with the AI investment spending. Could you talk about why now is the right moment to lean in further? And where do you see your AI investments turning into returns in the P&L? Would that mainly be stronger growth or margin expansion?
Tom Logan
executiveYeah. Quinn, there are really a lot of dimensions to this whole thing when we think about our AI spend, and I'll include cyber in that because, as we've seen most recently with this PHP exploitation, cyber risk is exploding absolutely, really driven by the enhanced capabilities that come from Anthropic and other frontier models overall. If we look at how AI dollars are being spent right now, it breaks down into roughly three wide categories. The first is data infrastructure, which is essentially enabling data to move without friction, with the right ontology, across the whole enterprise. Internal productivity is the second area. That means giving every one of our colleagues — from the executive suite all the way to the shop floor — AI tools, training them on those tools, and working through the process, really optimizing token spend as people move up that learning curve; we're watching that dynamic very closely, assigning each person the model that fits their needs, and continuing to monitor it as people build a more mature relationship with this technology. The third area concerns product development aimed at customers. Within that area, we've identified many dozens of initiatives in which we believe AI can substantially improve how useful an existing offering is — be it instrumentation, software, or a service we deliver to the customer. Our approach has been highly disciplined: we build a ranked hierarchy of priorities and confirm that the money we spend lines up with those initiatives as a whole. Still, to be clear, just as in every other area, AI costs come upfront. That means standing up the infrastructure, training our people, and carrying out the development work on customer-facing solutions that will be brought to market commercially. We haven't given guidance yet on when we expect to reach break-even on this, and we'll likely share more detail on that as we get closer to our Investor Day next year. But to be clear, we're strongly committed to this. We want to lead in AI. Based on feedback from Anthropic and others, we believe we are — broadly speaking, when compared with the industrial technology peer set. And we think this will ultimately generate enormous value for the enterprise. That said, when you account for the front-end loading — and the demands on both OpEx and CapEx — that has definitely played a part in our easing off somewhat on that margin target.
Quinn Fredrickson
analystAll right, thank you, Tom. My second question concerns Paragon. You went over the margins for it. Has anything shifted regarding revenue expectations? I believe you mentioned 25% pro forma growth, and considering where things stand year-to-date, ought we to expect a fairly large 4Q for Paragon? And if you could, please explain what would drive that.
Brian Schopfer
executiveYes, my recollection is that I said at least 25%. I think we remain extremely pleased with our position in that cycle from then on. The third quarter, Quinn, was their toughest comp, correct? That's the quarter in which they transacted; and I would say the fourth quarter is positioned well for success here, with really solid coverage and really solid momentum in the space. I think another interesting point, perhaps beneath the surface at Paragon, is that there's clearly a mix of nuclear power revenue coming through, plus a larger opportunity set and revenue within the DOE space, which we remain very excited about. So we feel good about our position there. We have an excellent team, and we're extremely pleased with where we stand from an execution standpoint, and we're highly confident in the fourth quarter.
Quinn Fredrickson
analystThank you, Brian.
Analyst
analystAanvi here, speaking in place of Joe. Good morning.
Tom Logan
executiveGood morning.
Analyst
analystHi. Yeah, thank you. I'd like to take a moment to focus on the order growth you're seeing and how that ties into the organic growth guidance as well. So in Q3, organic orders rose 62%, well ahead of your revenue growth for the quarter, and also ahead of your full-year guide. Could you speak to the mix you're seeing in orders today? What portion reflects multi-year projects rather than shorter-cycle orders? And what conversion profile do you expect over both the near term and the medium term?
Brian Schopfer
executiveLet me start with a general point. I believe we're actually seeing a wide mix across the order base, correct? We discussed a new build order in Q3; for what it's worth, I also referenced certain orders we received from EDF that aren't in our backlog. Those don't flow through our order rates. They aren't sitting in backlog today. We're waiting for those projects to be funded more broadly at the EU level. But those would be incremental new builds on top of what we saw even in Q3. The SMR figure actually wasn't the largest dynamic this quarter from a growth standpoint. In fact, we had negative order growth technically, right? Flat is probably the better description. The installed base, the DOE momentum from an order standpoint, all were quite encouraging. As you consider it, since we've been fielding lots of questions about, "Hey, is your backlog simply growing and going to convert much later down the line?" We included this page, I believe page seven of the presentation, the kind of beginning where it lays out just how this backlog kind of rolls off. We split that page between kind of the legacy business, so you could compare backwards in Paragon, so we didn't distort things. I think what you see here is, just within the current year, the legacy Mirion business, setting Paragon aside for a second, we have 18% more dollars in backlog to convert this year. Next year, that figure is up 26% after Q3, right? It continues from there. I think, two years out, so that would be 2028, is up 46%. Much smaller numbers, obviously. The point is we aren't just seeing backlog build that converts later. We're seeing backlog build and come in that converts nearer term, both in year this year, but also even into 2027. I think that's encouraging and is something we continue to believe will be something we continue to see into Q4. I think we're super encouraged about the order momentum and the backlog growth, but also how that will and is translating into revenue.
Analyst
analystGot it, that helps. Moving to my second question, I'd like to raise the Medical segment. So far there hasn't been much discussion of it, though this year's guidance involves a few pluses and minuses. I'm aware you've also got an easy comparison in Q4. It would be helpful if you could speak to the mid-single digit growth that's implied and to what you're actually seeing on the ground in RTQA.
Brian Schopfer
executiveYeah, well, I'd say our confidence in the order trends in Medical during Q4 — Q3, sorry — was quite strong. What I think made Q3 tough in particular is that it landed very late in the quarter, which isn't a shock. Hospital year-end activity is really a September phenomenon. Within Medical, that kind of pattern isn't out of the ordinary, and I believe it gives us some positioning advantage going into Q4. Regarding RTQA, it's genuinely interesting—we continue to observe strong software growth on the order side. On product, I'd characterize performance as okay this year, with the U.S. outperforming Europe. Once more, we're seeing encouraging signals in China, though we stay cautious there. Japan, from a recovery perspective, still looks somewhat tepid. That said, the team is performing well given how challenging the medical environment has been—a view you'd share if you looked more broadly. We do have some excellent new products. We've brought in some new leaders for that group, and that has us enthusiastic. Our stance on Medical for the coming periods is one of caution paired with optimism—that's the mindset we're carrying into the fourth quarter. Earlier, we had indicated the second quarter would come in a bit lower, though China was the real driver behind that. Excluding China from the year-ago period, you'd have seen growth in the mid-single digits or better. That pattern shows up once more this quarter, running somewhat below the high single-digit figure we posted. I'm aware of that gap. Our guidance calls for mid-single digit growth or above. That strikes me as a solid cadence for us, and we'll watch how we finish the year, then what that suggests for our 2027 guidance once we reach that point.
Analyst
analystThank you. That added detail is much appreciated.
Andy Kaplowitz
analystHello, all, and good morning.
Brian Schopfer
executiveAndy, good morning.
Andy Kaplowitz
analystTom or Brian, it's encouraging to see backlog growth in Q3. You talked about $125 million of new large bookings for Q4. You noted the $80 million already booked in Q4, but how does the large project award landscape as we head into 2027 stack up against the large project award landscape for 2026? As you're aware, there are clearly some sizable opportunities in Europe beyond France and potentially in the U.S. in 2027. Could you address Mirion's positioning to win them?
Tom Logan
executiveAndy, looking at the big picture, here's what we're observing — and let me begin with Nuclear before briefly addressing Medical, even though Nuclear accounts for most of this — namely that when it comes to new utility-scale construction opportunities, the pipeline continues to strengthen. A portion of it still doesn't qualify for inclusion in what we'd categorize as that high-engagement pipeline. Still, whenever we examine the fundamental forces at work for each of the major participants — Westinghouse, EDF Framatome, Rosatom, KEPCO and others among them — the signals we see are quite promising and, in my view, will underpin further expansion. We have not yet captured that in the close and large order pipeline. Yet to put it plainly, that trend only keeps improving. The next piece is the small modular reactor companies. I realize this is an area that makes people uneasy or that they treat with a fair amount of caution when they look at it as a whole. Our take, though, is more straightforward. We do agree that at some point — perhaps five years out, perhaps more, perhaps less — this sector will consolidate, going from what you could call more than 100 separate projects around the world to just a handful of companies that truly create this market and turn it into something strong and lasting overall. Still, our perspective is much simpler, and we believe there's an existential race underway here. Every developer of small modular technology has the same dream — to be SpaceX. They know they’re up against fierce competition in a fast-changing space, and there’s enormous pressure to advance swiftly and act with real boldness. The clearest example was the four new reactors reaching criticality around July 4th—an outright remarkable accomplishment. Still, when we consider the group of players that genuinely hold capital and have solid balance sheets, our view is that they will deploy that money, since they have no choice. To finish first overall, they must do so. On this point, I’d say we take great pride in where we stand. When you look at the instruments, services, and software we offer across the entire sector and sort them by life phase—those that have already changed hands versus those that haven't—we've established a very strong position in this sector, particularly when measured against our broader capabilities. We anticipate further expansion here, and we view it as possibly a bit more concrete than someone casually watching the market would, since we approach it with a capital-oriented lens rather than a broad macro-level one. The last element to address is the significant upgrade programs being carried out throughout the operating fleet, and once more we keep observing rising activity in that area, set off by choices to extend plant lifetimes and to uprate capacity, which in the end lead to upgrades of instrumentation packages. So regarding that overall situation, we hold a strongly positive view of how today's conditions will carry over into 2027 and later; yet this is not limited to nuclear power. I'd also point to the Department of Energy as probably the standout example. When we consider the project opportunities in the queue tied to environmental cleanup, upgrading our nuclear arsenal, and ongoing backing for advanced reactor technology development, we again see a really strong setup. So I'm answering your question at a broader level, but I want to be clear that when we examine the forces feeding that big order pipeline—which in turn feeds backlog—the picture is excellent.
Andy Kaplowitz
analystThat's useful context, Tom. Perhaps just to get us all on the same page. I realize the 30% margin goal is no longer in play, but if we consider what you're capable of on margin over the coming couple of years — I believe the prior pattern was that Mirion could achieve 50%+ incrementals. Should we be setting our sights there? Are there any pluses or minuses you'd flag for the next couple of years that we ought to factor in when thinking about incremental margin targets?
Tom Logan
executiveYeah. I'll go first, and Brian is going to wince. He can set me straight afterward. But once more, I'm extremely optimistic about the margin expansion story here. Our choice to essentially pull that 30-point near-term target comes really from the fact that it has turned into something of a distraction, and circumstances have shifted, especially regarding AI and cyber spending, along with the necessary front-end loading tied to all of that. Yet in my opinion, considering the strong operating leverage of the business, and again, all these self-help opportunities plus the Paragon integration path, and so on, as we look forward, there's a very significant chance for us to generate 1 to 2 points of margin expansion each year. Still, I think we'll give more refined guidance around that when we discuss our revised long range plan. Brian, how would you like to correct that?
Brian Schopfer
executiveNo, I believe everything you said is exactly right. We aren't stepping back from growing margins. What we want is to keep people from worrying that we'll push hard just to reach a target, and we want to be sure we keep running things well while staying responsible.
Andy Kaplowitz
analystThat's helpful, guys. Thank you.
Nick Amicucci
analystGood morning, everyone. I wanted to dig a bit deeper into the capital allocation question Brian asked earlier, if that's alright. Just thinking through Q4 and the opportunity set there. I get the 20/40/40 structure, but I suppose, how should we think about any potential acceleration in share repurchases, given where the stock is trading and that opportunity set?
Brian Schopfer
executiveYeah, I don't think we want to tip our hand on what we'll do there. What we do have to keep in mind in the fourth quarter is that we need to get the leverage printed down, for sure under 3x, and I think that's an absolute and has to happen in Q4; so regardless of what we do on either share repurchase or on the inorganic side, that 3x number has to have a 2x in front of it when we print at year-end, and we're very cognizant of that.
Nick Amicucci
analystUnderstood. You've brought this up a few times now, Brian, but I just want to make sure I have it right as well. So of that $125 million of incremental opportunity — the big pipeline still open for 2026 — $80 million relates to those European projects with EDF that you mentioned? That means we're talking about $45 million of incremental on top of that?
Brian Schopfer
executiveYes, that's right. Once again, we do actually have an order for those, but it can't go into our backlog until the EU provides formal funding for those six reactors; for what it's worth, those are all new build, and this was all part of the strategic deal we cut with EDF back two years ago. So we're super proud of the team for getting this done. But that will come into backlog and through orders once the funding happens; but yeah, there's roughly another $40 million-ish of other larger opportunities, which, look, would be quite a haul for the year. I'd also remind you, just on the orders topic one more time, why we're here. The fourth quarter last year was our largest ever orders quarter. FX was also — the euro was well above the $1.15; but also, we won a ton of orders, so that is just a dynamic to keep in mind here on the fourth quarter, even with that potential to win $125 million or $140 million of orders.
Nick Amicucci
analystUnderstood. Appreciate it, everyone.
Jeff Grampp
analystGood morning, folks.
Brian Schopfer
executiveGood morning.
Tom Logan
executiveGood morning.
Jeff Grampp
analystRegarding AI spending, Tom, I wanted to see if you could give us a bit more clarity there; it sounded like you're running ahead of budget, clearly. That's no surprise, but could you put some numbers on it in terms of where AI spending ends up landing this year, and should we expect that to keep growing into 2027, or how are you thinking about scaling those investments?
Brian Schopfer
executiveYeah. I'll take the P&L questions, perhaps. Look, I think, as I said, we're at nearly $4 million year-to-date, so through three quarters. That will clearly increase in the fourth quarter. My guess is it comes to $5 million or more in total by year-end. I do believe it will grow somewhat next year, certainly. Most of that currently sits at corporate. So a lot of that is in the corporate number, for what it's worth. But the benefits are landing in the business, right? Tom mentioned a lot of those. I'll tell you, on the Medical side, we're definitely seeing products released faster because of the spend. So timelines are speeding up. We had some new releases at one of the most recent shows, et cetera; so there's quite a bit of good dynamic happening underneath, but that's roughly where we'll land from a P&L perspective. On the CapEx side, you can add a couple million dollars to that, this year. It'll be less than what's been expensed through; that probably grows a bit next year as well as we keep building out the infrastructure.
Jeff Grampp
analystUnderstood. All right. Thanks for laying those details out. Turning to the bigger opportunities, clearly you highlighted a few of the uprate life extension announcements that have come out recently. Is any of that reflected in backlog as of the end of Q3? Does some of it sit in the large order pipeline, or how significant could a few of these announcements prove for Mirion?
Tom Logan
executiveWhen we consider the activity tied to life extension, yes, that does feed into some of the backlog, not just in the U.S. but in Europe as well. When it comes to uprate activity, there is somewhat more of a delay; so that is something still to come regarding how it might translate into opportunities for us.
Jeff Grampp
analystUnderstood. Thanks for the time, guys.
Tom Logan
executiveThanks, Jeff.
Brandon Knutson
analystMorning, guys, and I appreciate you taking my question. First off, the growth in backlog has been quite robust, and a portion of that backlog will be delivered across several years. Given that we're observing widespread inflation in input costs, what is everyone seeing regarding inflation, and how does pricing function within the backlog? Are you priced for that moving forward?
Brian Schopfer
executiveYeah. Look, inflation is definitely hitting us the same as everyone else. I believe the procurement initiatives we established a couple of years back have genuinely done a lot to keep us ahead of this. On a dollars basis, price cost this quarter was roughly flat. So on a rate basis, it costs us somewhat. Getting price in the market is something we keep pushing the teams on. Near term, it's somewhat simpler on the Medical side given the book-and-bill dynamic. It's somewhat tougher on the Nuclear & Safety side—not really to obtain price, but for it to flow through the P&L. On the bigger contracts, every new one we've signed includes escalation clauses tied to an appropriate index, depending on where that contract sits. From a large contract standpoint, we feel we have a very solid grip on our capacity to stay abreast of inflation. As supply and demand dynamics keep playing out, I think that likely works to our advantage on pricing. But price is a tough topic to discuss publicly simply because we don't want to reveal too much of our position; still, cost inputs are clearly rising. Our margin profile also benefits us, right? Even in places where we're seeing it, our capacity to pass it along has been solid. So that's roughly how we're viewing it right now.
Brandon Knutson
analystGreat. Thanks. Just a quick question about SMRs. I believe you mentioned that the orders booked this quarter come from 11 separate SMR providers, which demonstrates solid relationships among the many providers operating out there. I'd also guess that gives you decent visibility into how those projects are progressing. So have you noticed any slowdown in terms of, or perhaps just any, a slowdown regarding their ability to deliver on schedule, or any delays in that area?
Tom Logan
executiveNo, Brandon, I'd say what we're seeing is the reverse. What we're seeing is an acceleration, the sector strengthening as a whole. That isn't true across the board, but it is largely true, and I think it's a strong dynamic that timelines keep shifting to the left. Again, everything comes down to who holds capital and who has a mature Technology Readiness Level; but as a sector overall, we're seeing things progress somewhat faster and somewhat more tangibly.
Brandon Knutson
analystGreat, thanks.
Brian Schopfer
executiveCompetition in that area is genuinely fierce. Who comes out on top in that area is genuinely up for grabs, isn’t it? Or which couple comes out on top; so that’s definitely something you’re watching unfold, no question.
James West
analystGuys, good morning.
Tom Logan
executiveHey, James.
James West
analystTom, this is Brian. A few years back, you two provided an assumption of one dollar per megawatt for new builds. I believe at that point you were attempting to illustrate how much bigger that figure was for SMRs compared with AP1000s. Has that number been revised since the Paragon transaction? My assumption is that it is substantially higher. If you have a magnitude or a formal estimate, I would be very interested in hearing it.
Tom Logan
executiveNo, James, we have not. We will revisit that before next year's investor event. Directionally speaking, you are right. It stems from a blend of strengthened organic capabilities plus the inorganic side, mainly via Paragon and Certrec, which expand our wallet share. Additional elements feeding into this update include the fact that, when we provided that guidance a few years back, our default operating lifespan for a nuclear reactor was still 60 years. Now, I think arguably that figure would be 100. That will create a somewhat different dynamic. Our mix will differ, and our footprint will be wider. For utility-scale, that number will rise. Regarding the SMR dynamic, we clearly have accumulated a tremendous amount of knowledge concerning the various players, the various technologies, and ultimately where that center of gravity is heading. It really is too early to throw out a figure there, but I would simply keep adhering to the directional guidance we have previously provided that, on a per-megawatt basis, the opportunity set is substantially larger than it is for utility-scale.
James West
analystAll right, understood — that's reasonable. Thanks, Tom. Perhaps one quick follow-up regarding the SMRs and what competition looks like there. Brian touched on it, I believe, when answering one of the final questions. When these SMR companies create that sense of urgency, how does it affect your capacity to set pricing on those projects?
Tom Logan
executiveThere's an old expression: good, fast, cheap — pick two. We're genuinely good. We're capable of being genuinely fast. But when it comes to the marketplace, we're a premium-priced participant. Clearly, if you consider our performance record in the SMR sector up to now, once again, the team makes us very proud for what they've accomplished and truly built just incredible partnerships with most of these players, who are striving toward great things, and we want to walk alongside them hand in hand as they pursue those things. Once more, I'd point to the July 4th criticality events, which were just — I mean, astonishing how swiftly that came together and what it took to bring it about. Being part of that makes us proud; so our focus is squarely on being an excellent partner to the sector as a whole. Given that, I believe we'll receive fair compensation for it. But the dynamic thus far is pretty good.
James West
analystUnderstood. Thank you, Tom.
Tom Logan
executiveWell, everyone, we genuinely appreciate your time and attention today. Once again, we're very proud of how the enterprise performed, and a big thank-you goes out to all my Mirion colleagues around the world for delivering a strong quarter. But more importantly, I believe, setting us up for success in Q4 and into 2027. Thanks again for your time. We'll look forward to our next call a few months from now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.